Cardio Diagnostics Holdings, Inc. (CDIO)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cardio Diagnostics Holdings, Inc. (CDIO) trades at $2.03 with AI Score 19/100 (Grade F). Cardio Diagnostics Holdings, Inc. is a biotechnology company focused on developing advanced clinical diagnostic tools for cardiovascular disease. Market cap: $4.20M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for CDIO: CDIO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CDIO against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CDIO: 1/1 perspectives are bearish.
How is this calculated? →Cardio Diagnostics Holdings, Inc. (CDIO) Healthcare & Pipeline Overview
Cardio Diagnostics Holdings, Inc. specializes in advanced clinical diagnostics for cardiovascular disease, utilizing epigenetic insights to enhance risk assessment and promote preventative care in a rapidly evolving healthcare landscape.
What Is the Investment Thesis for CDIO?
Cardio Diagnostics Holdings, Inc. presents a compelling case for growth driven by its innovative Epi+Gen CHD test, which addresses a critical need in cardiovascular disease diagnostics. The company operates in a market projected to grow significantly due to increasing awareness of cardiovascular health and the demand for personalized medicine. With a profit margin of -40152.5% and a gross margin of -471.4%, the company is currently in a development phase, necessitating close monitoring of its ability to secure partnerships and achieve regulatory milestones. The successful commercialization of its products could lead to substantial revenue streams, particularly as the healthcare sector increasingly prioritizes preventative care. However, ongoing competition from established diagnostics firms poses a risk that could impact market share and growth potential.
Based on FMP financials and quantitative analysis
CDIO Key Highlights
- Market Cap of $4.20M indicates a nascent stage in the market.
- Profit Margin of -40152.5% reflects current operational challenges.
- Gross Margin of -471.4% indicates significant cost pressures in product development.
- Beta of 2.20 suggests higher volatility compared to the market.
- No dividend yield as the company reinvests in growth and development.
Who Are CDIO's Competitors?
CDIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DGX Quest Diagnostics Incorporated | $212.81 | -1.35% | $23.56B | 74 |
| LH Labcorp Holdings Inc. | $284.68 | -0.80% | $23.34B | 69 |
| MDXG MiMedx Group, Inc. | $4.03 | +2.03% | $600.25M | 92 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CDIO's Key Strengths?
- Innovative product offerings targeting cardiovascular diagnostics.
- Expertise in epigenetic insights enhances diagnostic accuracy.
- Strong focus on personalized medicine aligns with market demand.
What Are CDIO's Weaknesses?
- Current negative profit and gross margins indicate financial challenges.
- Limited operational scale with only 13 employees.
- Dependence on successful product development and regulatory approvals.
What Could Drive CDIO Stock Higher?
- Completion of regulatory approval processes for the Epi+Gen CHD test, which could enhance market entry.
- Development of strategic partnerships with healthcare providers to expand market reach and product validation.
- Continuous research and development efforts aimed at innovating new diagnostic tools and improving existing offerings.
What Are the Key Risks for CDIO?
- Financial-distress signal — its Altman Z-Score of -2.16 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-78.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles may impact the timeline for product launches and market entry.
- Intense competition from established players in the diagnostics market could affect market share.
- Financial instability due to negative profit margins may limit operational capabilities and growth.
What Are the Growth Opportunities for CDIO?
- Growth opportunity 1: The global cardiovascular diagnostics market is expected to reach $3.7 billion by 2026, driven by rising incidences of cardiovascular diseases and a growing focus on early detection. Cardio Diagnostics, with its Epi+Gen CHD test, is positioned to capture a share of this expanding market by offering innovative solutions that leverage epigenetic insights.
- Growth opportunity 2: The increasing demand for personalized medicine presents a significant opportunity for Cardio Diagnostics. As healthcare shifts towards tailored treatment plans, the company's focus on risk stratification tools aligns with market needs. This trend is expected to grow, with personalized medicine projected to reach $2.4 trillion by 2028, providing a favorable environment for Cardio Diagnostics' offerings.
- Growth opportunity 3: Strategic partnerships with healthcare providers and research institutions could enhance Cardio Diagnostics' market reach and credibility. Collaborations that focus on clinical trials and product validation can accelerate the adoption of their diagnostic tools, positioning the company as a leader in cardiovascular diagnostics.
- Growth opportunity 4: Regulatory approvals for innovative diagnostic tests can significantly boost market entry and credibility. Cardio Diagnostics is actively pursuing necessary certifications and approvals, which could facilitate access to broader markets and enhance trust among healthcare professionals and patients alike.
- Growth opportunity 5: The rise of telemedicine and remote patient monitoring creates avenues for Cardio Diagnostics to integrate its diagnostic tools into digital health platforms. By leveraging technology, the company can expand its reach and provide accessible solutions for cardiovascular risk assessment, aligning with the trend towards digital healthcare.
What Opportunities Does CDIO Have?
- Expanding global cardiovascular diagnostics market presents growth potential.
- Increasing demand for personalized medicine supports business model.
- Potential for strategic partnerships to enhance credibility and market access.
What Threats Does CDIO Face?
- Intense competition from established diagnostics companies.
- Regulatory hurdles may delay product launch and market entry.
- Market volatility could impact funding and operational stability.
What Are CDIO's Competitive Advantages?
- Unique epigenetic approach to cardiovascular diagnostics.
- Focus on personalized medicine aligns with market trends.
- Innovative product offerings that differentiate from competitors.
- Potential for strategic partnerships to enhance market presence.
What Does CDIO Do?
Founded in 2017 and headquartered in Chicago, Illinois, Cardio Diagnostics Holdings, Inc. is dedicated to developing advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. The company’s flagship product, Epi+Gen CHD, is a groundbreaking test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. By focusing on risk stratification, Cardio Diagnostics aims to improve early detection and personalized treatment plans, responding to the growing demand for preventative cardiovascular care. The company operates in a highly competitive market, where established players dominate, yet it strives to carve out a niche through innovative technology and strategic partnerships. With a small team of 13 employees, Cardio Diagnostics is positioned to rapidly adapt to the evolving landscape of healthcare diagnostics, emphasizing the importance of personalized medicine in improving patient outcomes. As the global focus on preventative healthcare intensifies, Cardio Diagnostics is well-placed to contribute significantly to the field of cardiovascular diagnostics, offering unique insights that could redefine patient care.
What Products and Services Does CDIO Offer?
- Develop advanced clinical diagnostic tools for cardiovascular disease.
- Leverage epigenetic insights to create innovative testing solutions.
- Offer the Epi+Gen CHD test to assess risk for coronary heart disease.
- Focus on risk stratification for improved patient outcomes.
- Aim to enhance early detection and personalized treatment plans.
- Engage in partnerships to expand market reach and product validation.
How Does CDIO Make Money?
- Generate revenue through the sale of diagnostic tests.
- Engage in partnerships with healthcare providers for product distribution.
- Focus on research and development to innovate new diagnostic solutions.
- Leverage grants and funding for product development and clinical trials.
What Industry Does CDIO Operate In?
The biotechnology industry is witnessing rapid advancements, particularly in diagnostics, driven by technological innovations and a growing emphasis on personalized medicine. The global cardiovascular diagnostics market is projected to grow significantly, fueled by increasing prevalence of cardiovascular diseases and the demand for early detection tools. Cardio Diagnostics Holdings, Inc. operates within this dynamic landscape, aiming to differentiate itself through its unique epigenetic approach. Competition is intense, with established players dominating the market, yet the increasing focus on preventative care presents opportunities for innovative solutions like those offered by Cardio Diagnostics.
Who Are CDIO's Key Customers?
- Healthcare providers seeking advanced diagnostic tools.
- Patients at risk of cardiovascular diseases.
- Research institutions focusing on cardiovascular health.
- Pharmaceutical companies looking for diagnostic solutions for clinical trials.
FY2026 estForward Outlook
Wall Street analysts project Cardio Diagnostics Holdings, Inc. revenue of about $25.0M for fiscal 2026, with EPS near $-16.50.
CDIO Valuation & Market Position
With a $4.20M market cap, Cardio Diagnostics Holdings, Inc. sits in the micro-cap segment of the market. Relative to its peer group, CDIO's quantitative score of 19/100 is below the peer average of 79/100.
ROE -79%Key Financial Metrics
Return on equity for Cardio Diagnostics Holdings, Inc. stands at -78.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -69.6%, showing how much profit it generates from its asset base. A current ratio of 15.76 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -106.9%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
Cardio Diagnostics Holdings, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.16 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Cardio Diagnostics Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Chicago, US. The company is led by CEO Meeshanthini V. Dogan. CDIO has traded publicly since 2022.
CDIO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Innovative product offerings targeting cardiovascular diagnostics.
- Expertise in epigenetic insights enhances diagnostic accuracy.
- Strong focus on personalized medicine aligns with market demand.
- Upcoming: Completion of regulatory approval processes for the Epi+Gen CHD test, which could enhance market entry.
Bear Case
- Current negative profit and gross margins indicate financial challenges.
- Limited operational scale with only 13 employees.
- Dependence on successful product development and regulatory approvals.
- Potential: Regulatory hurdles may impact the timeline for product launches and market entry.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
CDIO Latest News
-
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga · May 26, 2026
CDIO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CDIO.
Price Targets
Wall Street price target analysis for CDIO.
CDIO MoonshotScore
What does this score mean?
The MoonshotScore rates CDIO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Meeshanthini V. Dogan
CEO
Meeshanthini V. Dogan has a strong background in biotechnology and healthcare management, having held various leadership roles in the industry. With a focus on innovation and strategic growth, she has been instrumental in guiding Cardio Diagnostics since its inception in 2017. Her educational background includes advanced degrees in biomedical sciences and healthcare administration, equipping her with the skills necessary to lead a cutting-edge diagnostics company.
Track Record: Under her leadership, Cardio Diagnostics has developed its flagship Epi+Gen CHD test and is actively pursuing regulatory approvals. Meeshanthini's strategic vision has positioned the company to capitalize on emerging trends in cardiovascular diagnostics.
What Investors Ask About Cardio Diagnostics Holdings, Inc. (CDIO) — Healthcare
What does Cardio Diagnostics Holdings, Inc. do?
Cardio Diagnostics Holdings, Inc. specializes in developing advanced clinical diagnostic tools for cardiovascular disease, utilizing epigenetic insights to create innovative tests. Their flagship product, Epi+Gen CHD, assesses an individual's risk for developing symptomatic coronary heart disease, aiming to improve early detection and personalized treatment plans.
What are the main risks for CDIO?
The primary risks for Cardio Diagnostics Holdings, Inc. include regulatory hurdles that may delay product launches, intense competition from established diagnostics companies that could affect market share, and financial instability due to negative profit margins that may limit operational capabilities and growth potential.
How does Cardio Diagnostics Holdings, Inc. manage patent expiration risks?
Cardio Diagnostics Holdings, Inc. focuses on continuous innovation and development of new diagnostic tools to mitigate the risks associated with patent expirations. By maintaining a robust research and development pipeline, the company aims to stay ahead of competitors and ensure a steady flow of new products that can capture market interest.
What are the key factors to evaluate for CDIO?
Cardio Diagnostics Holdings, Inc. (CDIO) holds an AI score of 19/100 (low). Not financial advice.
How frequently does CDIO data refresh on this page?
CDIO prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CDIO's recent stock price performance?
Cardio Diagnostics Holdings, Inc. (CDIO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product offerings targeting cardiovascular diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CDIO overvalued or undervalued right now?
Valuing Cardio Diagnostics Holdings, Inc. (CDIO) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CDIO?
Before investing in Cardio Diagnostics Holdings, Inc. (CDIO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data derived from company profile and existing financial insights.